Antengene Secures Clinical Trial Approval in Australia for Innovative ATG-201 Treatment
Antengene Corporation has received approval for a Phase I clinical trial of ATG-201, a groundbreaking treatment for B cell-related autoimmune diseases. This development marks a significant step forward in addressing complex autoimmune conditions globally.